Luca Cericola

Oct 30, 2024 | inquisitiveminds.bristows.com | Matthew Warren |Luca Cericola |James Johnston

On 24 October 2024, Cancer Research UK ("CRUK") and KisoJi Biotechnology Inc. ("KBI") announced that they have entered into an agreement to advance KBI's lead antibody, KJ-103, into a first-in-human Phase 1/2a clinical trial at CRUK's Centre for Drug Development.

Aug 19, 2024 | inquisitiveminds.bristows.com | Claire Smith |Luca Cericola

Vertex Pharmaceuticals announced a reimbursement agreement with NHS England for individuals 12 years or older with transfusion-dependent beta thalassemia ("TDT") to access the CRISPR/Cas9 gene-edited therapy, CASGEVY (exagamglogene autotemcel), from 8 August 2024. The agreement is limited to people living with TDT for whom a stem cell or bone marrow transplant is appropriate but no donor is available.

Jun 11, 2024 | lexology.com | Claire Smith |Luca Cericola

Cell and gene therapies (CGTs) continue to hold considerable promise for the future of medicine, providing unprecedented therapeutic potential for the treatment of even the most intractable diseases. Deal-making in this space continues to rise with, according to a recent IQVIA report: (i) the number of CGT deals increasing by 48% over the last decade; and (ii) associated venture capital activity surpassing $3 billion last year.